The success of Imatinib validated the concept of targeted cancer therapy and paved the way for the development of other targeted treatments. Its approval in 2001 by the FDA marked a paradigm shift in oncology, demonstrating that it was possible to design therapies that specifically target the molecular abnormalities driving cancer growth. This has led to a wave of new drugs targeting various cancers, fundamentally changing the landscape of cancer treatment.
